A panelist discusses the evolving role of prophylactic tocilizumab in reducing cytokine release syndrome during bispecific antibody therapy, enabling outpatient treatment and improving patient ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback